238 related articles for article (PubMed ID: 35967571)
1. Discontinuation of tyrosine kinase inhibitors based on
Kim Y; Kim S; Lee JM; Ahn A; Yoo JW; Lee JW; Cho B; Chung NG; Kim Y; Kim M
Front Pediatr; 2022; 10():928136. PubMed ID: 35967571
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
3. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
4. Effect of
Park H; Kim HJ; Sohn SK; Baik Y; Kim D; Lee SY; Kong JH; Kim H; Shin DY; Ahn JS; Park J; Park S; Kim I
Ther Adv Hematol; 2023; 14():20406207231205637. PubMed ID: 37929079
[TBL] [Abstract][Full Text] [Related]
5. Droplet Digital PCR for
Bochicchio MT; Petiti J; Berchialla P; Izzo B; Giugliano E; Ottaviani E; Errichiello S; Rege-Cambrin G; Venturi C; Luciano L; Daraio F; Calistri D; Rosti G; Saglio G; Martinelli G; Pane F; Cilloni D; Gottardi EM; Fava C
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771634
[No Abstract] [Full Text] [Related]
6. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX
Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
[TBL] [Abstract][Full Text] [Related]
9. Digital PCR can provide improved
Smitalova D; Dvorakova D; Racil Z; Romzova M
Pract Lab Med; 2021 May; 25():e00210. PubMed ID: 33778144
[No Abstract] [Full Text] [Related]
10. Committed change of real-time quantitative PCR to droplet digital PCR for monitoring
Kongruang A; Limsuwanachot N; Magmuang S; Areesirisuk P; Niparuck P; Siriboonpiputtana T; Rerkamnuaychoke B
Hematology; 2023 Dec; 28(1):2256199. PubMed ID: 37695125
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.
Cortés AA; Olmedillas S; Serrano-López J; Lainez-González D; Castaño T; Iñiguez R; Lopez-Lorenzo JL; García A; Atance M; Sánchez RNS; Lopez CB; Arranz MG; Sillero PL; Alonso-Dominguez JM
Mol Diagn Ther; 2020 Oct; 24(5):593-600. PubMed ID: 32875515
[TBL] [Abstract][Full Text] [Related]
12. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
[TBL] [Abstract][Full Text] [Related]
13. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.
Martinez RJ; Kang Q; Nennig D; Bailey NG; Brown NA; Betz BL; Tewari M; Thyagarajan B; Bachanova V; Mroz P
Arch Pathol Lab Med; 2022 Jan; 146(1):92-100. PubMed ID: 33769465
[TBL] [Abstract][Full Text] [Related]
14. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
[TBL] [Abstract][Full Text] [Related]
16. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
Yoshida C; Yamaguchi H; Doki N; Murai K; Iino M; Hatta Y; Onizuka M; Yokose N; Fujimaki K; Hagihara M; Oshikawa G; Murayama K; Kumagai T; Kimura S; Najima Y; Iriyama N; Tsutsumi I; Oba K; Kojima H; Sakamaki H; Inokuchi K;
Int J Hematol; 2023 May; 117(5):694-705. PubMed ID: 36739328
[TBL] [Abstract][Full Text] [Related]
17. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
Clark RE; Polydoros F; Apperley JF; Milojkovic D; Pocock C; Smith G; Byrne JL; de Lavallade H; O'Brien SG; Coffey T; Foroni L; Copland M
Lancet Haematol; 2017 Jul; 4(7):e310-e316. PubMed ID: 28566209
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
20. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
Alikian M; Gale RP; Apperley JF; Foroni L
Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
